EG 427, a Paris-based BioTech startup focused on the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful closing of a €27 million Series B financing round
The funding round was Co-led by Andera Partners and Bpifrance as part of the InnoBio investment strategy.
MTS Health Partners served as exclusive financial advisor to EG 427 in this financing round.
“The successful closing of this Series B financing is a major milestone for EG 427, which brings us the strong support of two major institutional investors, Andera Partners and Bpifrance, participation of the specialist fund, SCI Ventures, and the continuous support of our existing investors. Genetic medicine solutions have the potential to address major medical needs affecting large patient population with chronic diseases.
“Initially, our focus is on pathologies in neuro-urology. This field is currently underserved and lacks significant recent medical innovations, despite its huge costs to the healthcare systems. This funding allows us to advance our first program focussed on dysfunctions of the bladder, such as neurogenic bladder, through its initial clinical trial. This first human study, currently in progress, will provide a read on safety and possibly early efficacy,” said Philippe Chambon, MD, PhD, Chief Executive Officer at EG 427.
Founded in 2019 by Philippe Chambon, Alberto Epstein, François Giuliano, Pierre Denys, and Charles Joussain, EG 427 is innovating in non-replicating HSV-1 (nrHSV-1) vector technology in neurology.
According to the company, it is the first human study of such a vector, targeting sensory neuron-based diseases. The product, EG110A, addresses multiple severe bladder diseases, such as neurogenic bladder (NDO) and overactive bladder (OAB), and has the potential to be a major improvement over existing therapies, resulting in better care for patients and lower costs for healthcare systems.
EG110A is a genetic medicine utilising a non-replicating HSV-1 vector, which has been designed to selectively silence the signals of key bladder sensory neurons responsible for the bladder muscle overactivity, whilst preserving bladder voiding function. NDO is a common urinary bladder dysfunction caused by SCI and other neurodegenerative diseases, such as multiple sclerosis or Parkinson’s disease.
The company’s HERpes Modular Expression System (HERMES) platform delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Its vectors can achieve focal transduction in specific regions and then selective expression of transgenes in targeted subsets of neurons thanks to the control of sophisticated regulatory elements. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of nrHSV-1 vectors allows for versatile DNA delivery for smarter genetic medicine.
“As a world leader in developing non-replicative HSV vectors in neurology, EG 427 has the potential to significantly advance the applications of genetic medicine through highly targeted delivery and local administration. In addition, EG 427’s platform could enable repeated dosing and more affordable production costs compared to AAV based vectors. If successful, this approach could offer a better and longer-term therapeutic solution for patients who suffer from chronic neurological diseases,” said Benoît Barteau, Investment Director at Bpifrance – InnoBio funds.
The proceeds from the financing will be used to fund the phase 1b/2a development of EG 427’s lead genetic medicine product, EG110A, for the treatment of neurogenic detrusor overactivity (NDO) in spinal cord injury (SCI) patients. This US study, the company says, could open the way for clinical development across a series of medically important but neglected neuro-urology pathologies affecting millions of patients.
The financing will also support expansion of EG 427’s pipeline with several therapeutic vectors based on its HERMES technology. In these targeted diseases, this technology has the ability to maintain long-term activity and achieve low cost of goods, which should provide strong medical and economic value to the healthcare systems.
“EG 427’s technology has the potential to significantly disrupt current treatment paradigms. The lead programme EG110A could significantly improve treatment options for a range of underserved neuro-urology indications. We are thrilled to have co-led this financing round to advance EG110A in the clinic and EG 427’s broader genetic medicine pipeline,” said Raphaël Wisniewski, Partner at Andera Partners.
Read the orginal article: https://www.eu-startups.com/2025/02/biotech-startup-eg-427-raises-e27-million-to-tackle-chronic-diseases-in-neurology/
